샘플 요청 목록

 카트 문의
시장보고서
상품코드
1774974

세계의 잠복 결핵 감염 감지 시장

Latent Tuberculosis Infection Detection
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 464 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 잠복 결핵 감염 감지 시장은 2030년까지 22억 달러에 도달

2024년에 18억 달러로 추정되는 잠복 결핵 감염 감지 세계 시장은 2024-2030년간 CAGR 3.6%로 성장하여 2030년에는 22억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 QFT 플러스 브랜드는 CAGR 3.0%를 나타내고, 분석 기간 종료시에는 14억 달러에 이를 것으로 예측됩니다. 기타 브랜드 부문의 성장률은 분석 기간중 CAGR 4.7%로 추정됩니다.

미국 시장은 4억 8,760만 달러로 추정, 중국은 CAGR 6.6%로 성장 예측

미국의 잠복 결핵 감염 감지 시장은 2024년에 4억 8,760만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 4억 4,110만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 6.6%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.5%와 2.8%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.1%로 성장할 전망입니다.

세계의 잠복 결핵 감염 감지 시장 - 주요 동향과 촉진요인 정리

잠복 결핵 감염(LTBI)이란 무엇이며, 왜 조기발견이 중요한가?

잠복 결핵 감염(LTBI)은 결핵균에 감염되었으나 활동성 증상이나 질병의 징후가 나타나지 않을 때 발생하며, LTBI 환자는 전염성이 없지만, 특히 면역력이 저하된 경우 활동성 결핵으로 발전할 위험이 있습니다. LTBI의 조기 발견과 치료는 심각한 건강 합병증을 유발하고 다른 사람에게 전염시킬 수 있는 활동성 결핵으로의 진행을 막기 위해 매우 중요하며, LTBI의 진단은 보통 피부 검사나 혈액 검사를 통해 체내 결핵균의 존재를 감지하는 방식으로 이루어집니다.

세계 결핵 발병률 증가, 특히 의료 인프라가 열악한 신흥국에서의 결핵 발병률 증가는 첨단 LTBI 검출 방법에 대한 수요를 촉진하고 있습니다. 기존의 피부 검사가 표준이었으나, 인터페론-γ 방출 측정법(IGRA)과 같은 새로운 혈액 기반 검사는 높은 정확도와 빠른 결과 제공 능력으로 인기를 얻고 있으며, LTBI의 정확한 검출은 결핵의 확산을 억제하고 활동성 결핵 발병을 예방하기 위한 치료를 적시에 시작하는 데 필수적입니다. 적시에 치료를 시작하는 데 필수적입니다.

진단 기술의 발전은 LTBI 검출 시장에 어떤 영향을 미치고 있는가?

진단 기술의 발전으로 결핵균 검출의 정확성, 속도, 접근성이 크게 향상되었으며, PCR 기반 검사와 같은 분자진단법은 결핵균을 조기에 검출하기 위해 사용되고 있으며, 기존 방법에 비해 더 빠른 결과와 높은 민감도를 제공합니다. 또한, 휴대용 및 현장 진단 도구의 개발은 특히 실험실 인프라가 부족한 원격지나 자원이 부족한 환경에서 LTBI 검사에 대한 접근성을 개선하고 있습니다. 이러한 기술 혁신은 의료 종사자, HIV 감염자, 활동성 결핵 환자와 밀접하게 접촉하는 사람 등 결핵 고위험군 집단에서 LTBI를 식별하는 데 매우 중요합니다.

QuantiFERON-TB 골드 테스트와 같은 새로운 혈액 검사도 BCG 백신 접종 이력 등의 요인에 영향을 받을 수 있는 투베르쿨린 피부 테스트(TST)에 비해 LTBI를 진단할 수 있는 보다 신뢰할 수 있는 방법을 제공함으로써 감지를 개선하고 있습니다. 또한, 디지털 건강 도구와 원격 의료를 진단 프로세스에 통합함으로써 LTBI 검사의 범위와 효율성이 확대되고 있습니다. 이러한 발전은 활동성 결핵으로 진행될 위험이 있는 개인을 더 쉽게 식별할 수 있게 하여 궁극적으로 전 세계 결핵의 부담을 줄이는 데 기여하고 있습니다.

LTBI 검출 시장의 성장 촉진요인은 무엇인가?

LTBI 검출 시장의 성장을 가속하는 주요 요인은 결핵의 전 세계 유병률 증가와 보다 정확하고 효율적인 검출 방법의 필요성입니다. 결핵은 특히 중저소득 국가에서 여전히 공중보건의 주요 관심사이기 때문에 LTBI를 조기에 발견할 수 있는 신뢰할 수 있고 비용 효율적인 진단 도구에 대한 수요가 증가하고 있습니다. 특히 결핵 발병률이 높은 지역으로부터 전 세계 이민자 증가도 LTBI 검진 및 진단에 대한 수요 증가에 기여하고 있습니다.

또한, 각국 정부와 보건기관이 잠재적 감염자를 대상으로 한 결핵 퇴치 노력을 강화하면서 조기 진단과 치료가 더욱 중요시되고 있습니다. 혈액검사, 분자진단 등 진단기술의 발전으로 LTBI 검출의 속도와 정확도가 향상되어 고위험군에 대한 접근성과 경제성이 향상되고 있습니다. 결핵 퇴치를 위한 전 세계 보건 활동의 확대와 자금 지원은 LTBI 검출이 전 세계 결핵 퇴치 프로그램의 필수적인 부분으로 자리 잡으면서 시장 성장을 더욱 촉진하고 있습니다.

LTBI 검출 시장의 주요 성장 촉진요인은 무엇인가?

LTBI 검출 시장의 성장은 전 세계 결핵 발병률 증가, 보다 신속하고 정확한 진단 방법에 대한 수요 증가, 결핵 확산을 방지하기 위해 LTBI를 감지하고 치료하는 것의 중요성에 대한 인식 증가 등 여러 가지 요인에 의해 이루어지고 있습니다. 결핵 퇴치를 위한 세계 보건 프로그램의 확대와 진단 기술의 발전으로 조기 발견 방법에 대한 접근성이 확대되고 있습니다. 또한, 국경 간 이동 증가와 예방적 건강관리의 중요성이 강조되면서 전 세계적으로 LTBI 검사에 대한 수요가 증가하고 있습니다. 각국이 결핵 퇴치를 최우선 과제로 삼고 있는 가운데, 효과적인 LTBI 검출 및 검진에 대한 수요는 계속 증가할 것이며, 결핵 퇴치가 세계 보건 활동의 최전선에서 계속 유지될 것입니다.

부문

브랜드(QFT-Plus 브랜드, 기타 브랜드), 검사 유형(tuberculin 피부 테스트 유형, 인터페론γ방출 어세이 테스트 유형), 최종 용도(진단실험실 최종 용도, 병원/진료소 최종 용도, 학술기관 및 연구기관 최종 용도), 용도(폐결핵 가정 내 접촉자 용도, PLHIV 용도, 기타 용도)

조사 대상 기업 예

  • Abbott Laboratories
  • ARKRAY, Inc.
  • Becton, Dickinson and Company(BD)
  • Beijing Wantai Biological Pharmacy
  • bioMerieux S.A.
  • Bio-Rad Laboratories, Inc.
  • Cepheid
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Lionex GmbH
  • Luminex Corporation
  • Oxford Immunotec Global PLC
  • Par Pharmaceutical, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Sanofi S.A.
  • SD Biosensor, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Thermo Fisher Scientific Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.31

Global Latent Tuberculosis Infection Detection Market to Reach US$2.2 Billion by 2030

The global market for Latent Tuberculosis Infection Detection estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. QFT-Plus Brand, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Other Brands segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$487.6 Million While China is Forecast to Grow at 6.6% CAGR

The Latent Tuberculosis Infection Detection market in the U.S. is estimated at US$487.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$441.1 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Latent Tuberculosis Infection Detection Market - Key Trends & Drivers Summarized

What Is Latent Tuberculosis Infection (LTBI) and Why Is Early Detection Critical?

Latent Tuberculosis Infection (LTBI) occurs when a person is infected with the tuberculosis (TB) bacteria but does not exhibit active symptoms or show signs of disease. People with LTBI are not contagious, but they are at risk of developing active TB, especially if their immune system becomes weakened. Early detection and treatment of LTBI are crucial to prevent the progression to active TB, which can cause serious health complications and be transmitted to others. The diagnostic process for LTBI typically involves skin tests or blood tests that detect the presence of the TB bacteria in the body.

The increasing incidence of TB globally, particularly in developing countries with limited healthcare infrastructure, has spurred the demand for advanced LTBI detection methods. While traditional skin tests have been the standard, newer blood-based tests, such as the interferon-gamma release assays (IGRAs), are gaining popularity due to their greater accuracy and ability to provide quicker results. Accurate detection of LTBI is essential for controlling the spread of TB and for initiating timely treatment to prevent the development of active TB.

How Are Advancements in Diagnostic Technologies Impacting the LTBI Detection Market?

Advancements in diagnostic technologies have significantly improved the accuracy, speed, and accessibility of LTBI detection. Molecular diagnostics, such as PCR-based tests, are increasingly being used to detect TB bacteria at an early stage, providing faster results and greater sensitivity compared to traditional methods. Additionally, the development of portable and point-of-care diagnostic tools is improving access to LTBI testing, particularly in remote or resource-limited settings where laboratory infrastructure may be lacking. These innovations are crucial for identifying LTBI in populations that are at high risk for TB, such as healthcare workers, individuals living with HIV, and those in close contact with active TB patients.

Newer blood tests, such as the QuantiFERON-TB Gold test, are also improving detection by offering a more reliable method for diagnosing LTBI compared to the tuberculin skin test (TST), which can be influenced by factors such as prior BCG vaccination. Furthermore, the integration of digital health tools and telemedicine into the diagnostic process is expanding the reach and efficiency of LTBI testing. These advancements are making it easier to identify individuals who are at risk for progressing to active TB, ultimately helping reduce the global burden of TB.

What Are the Primary Drivers of the LTBI Detection Market's Growth?

The primary drivers behind the growth of the LTBI detection market are the increasing global prevalence of tuberculosis and the need for more accurate, efficient detection methods. As TB remains a major public health concern, particularly in low-income and middle-income countries, there is growing demand for reliable and cost-effective diagnostic tools to identify LTBI early. The rise in global migration, particularly from regions with high TB prevalence, is also contributing to the increased demand for LTBI screening and detection.

Furthermore, as governments and health organizations intensify efforts to eliminate TB by targeting latent infections, there is greater emphasis on early diagnosis and treatment. Advancements in diagnostic technology, such as blood-based tests and molecular diagnostics, are improving the speed and accuracy of LTBI detection, making them more accessible and affordable for high-risk populations. The expansion of global health initiatives and funding aimed at TB eradication is further propelling market growth, ensuring that LTBI detection is an integral part of global TB control programs.

What Are the Key Growth Drivers for the LTBI Detection Market?

The growth in the LTBI detection market is driven by several factors, including the increasing incidence of tuberculosis globally, the rising demand for faster and more accurate diagnostic methods, and growing awareness about the importance of detecting and treating LTBI to prevent the spread of TB. The expansion of global health programs aimed at TB eradication, along with advancements in diagnostic technologies, is providing greater access to early detection methods. Additionally, the increasing movement of people across borders and the greater emphasis on preventive healthcare are also driving the demand for LTBI testing worldwide. As countries continue to prioritize TB control, the demand for effective LTBI detection and screening will continue to grow, ensuring that the fight against tuberculosis remains at the forefront of global health efforts.

SCOPE OF STUDY:

The report analyzes the Latent Tuberculosis Infection Detection market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Brand (QFT-Plus Brand, Other Brands); Test Type (Tuberculin Skin Test Type, Interferon Gamma Released Assay Test Type); End-Use (Diagnostic Laboratories End-Use, Hospitals / clinics End-Use, Academic & Research Institutions End-Use); Application (Household Contacts with Pulmonary TB Application, PLHIV Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Abbott Laboratories
  • ARKRAY, Inc.
  • Becton, Dickinson and Company (BD)
  • Beijing Wantai Biological Pharmacy
  • bioMerieux S.A.
  • Bio-Rad Laboratories, Inc.
  • Cepheid
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Lionex GmbH
  • Luminex Corporation
  • Oxford Immunotec Global PLC
  • Par Pharmaceutical, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Sanofi S.A.
  • SD Biosensor, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Latent Tuberculosis Infection Detection - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global TB Elimination Initiatives Throw the Spotlight on Early Latent TB Detection Technologies
    • High Prevalence of Latent TB in High-Burden Regions Expands Addressable Market Opportunity
    • Integration of Latent TB Screening in Routine Health Programs Spurs Adoption Across Primary Healthcare Settings
    • Development of Novel Biomarker-Based Diagnostic Tools Propels Market Growth Through Higher Accuracy and Specificity
    • Adoption of Interferon Gamma Release Assays (IGRAs) Strengthens Business Case for Blood-Based Latent TB Testing
    • Scaling National Screening Programs in Developing Countries Generates Demand for Affordable and Rapid Diagnostic Kits
    • Mandatory Pre-Employment and Immigration Screening Protocols Drive Growth in Occupational and Travel Health Markets
    • Increasing Research Investments in Latent TB Immunology Accelerates Diagnostic Innovation and Pipeline Expansion
    • Emergence of AI and Data Analytics in TB Risk Stratification Enhances Precision Screening and Drives Adoption
    • Heightened Focus on Preventing TB Reactivation in Immunocompromised Populations Propels Screening Demand
    • WHO Guidelines Endorsing Systematic Testing in High-Risk Groups Strengthen Global Regulatory Push
    • Rising Awareness Through Global TB Campaigns Sustains Public Health-Driven Demand for Latent TB Detection
    • Public-Private Partnerships in TB Control Programs Create Opportunities for Technology Deployment at Scale
    • Growing Use of Digital Health Platforms to Track and Monitor TB Infections Drives Integration of Remote Diagnostic Tools
    • Shift Toward Decentralized Diagnostic Models Expands Reach of Latent TB Testing in Rural and Low-Infrastructure Settings
    • Demand for Pediatric TB Diagnosis Throws the Spotlight on Age-Specific Latent TB Detection Challenges and Solutions
    • Growing Global Migration Trends Spur Latent TB Testing Demand in Border and Resettlement Health Programs
    • Increased Funding From Global Health Agencies Accelerates Commercialization of Next-Generation Diagnostic Platforms
    • Healthcare System Preparedness Post-Pandemic Strengthens Focus on Infectious Disease Surveillance and Latent TB Inclusion
    • Stringent Regulatory Frameworks for TB Elimination and Surveillance Programs Create Both Compliance Pressures and Market Incentives
    • Rising Co-Infection Rates with HIV and Diabetes Drive Multidisciplinary Screening Protocols and Diagnostic Integration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Latent Tuberculosis Infection Detection Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Latent Tuberculosis Infection Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Latent Tuberculosis Infection Detection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for QFT-Plus Brand by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for QFT-Plus Brand by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for QFT-Plus Brand by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Brands by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Other Brands by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Other Brands by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Household Contacts with Pulmonary TB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Household Contacts with Pulmonary TB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Household Contacts with Pulmonary TB Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for PLHIV Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for PLHIV Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for PLHIV Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Tuberculin Skin Test Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Tuberculin Skin Test Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Tuberculin Skin Test Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Interferon Gamma Released Assay Test Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Interferon Gamma Released Assay Test Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Interferon Gamma Released Assay Test Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals / clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospitals / clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hospitals / clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Academic & Research Institutions End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Latent Tuberculosis Infection Detection by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 98: France Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 134: UK Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: UK 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Spain 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Spain 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Spain 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 158: Russia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Russia Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Russia 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 161: Russia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Russia Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Russia 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Russia 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 170: Rest of Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Europe Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Europe Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 182: Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 183: Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 197: Australia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Australia Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Australia 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 200: Australia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Australia Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Australia 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Australia 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • INDIA
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 209: India Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: India Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: India 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 212: India Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: India Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: India 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 215: India Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: India 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 218: India Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 221: South Korea Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: South Korea Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: South Korea 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 224: South Korea Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: South Korea Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: South Korea 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: South Korea 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 233: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 245: Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Latin America Historic Review for Latent Tuberculosis Infection Detection by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 248: Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Latin America Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 260: Argentina Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Argentina Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Argentina 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 263: Argentina Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Argentina Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Argentina 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Argentina 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 272: Brazil Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Brazil Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Brazil 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 275: Brazil Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Brazil Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Brazil 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Brazil 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 284: Mexico Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Mexico Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Mexico 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 287: Mexico Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Mexico Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Mexico 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Mexico 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 296: Rest of Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Latin America Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Latin America Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 308: Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 309: Middle East Historic Review for Latent Tuberculosis Infection Detection by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 311: Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Middle East Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 323: Iran Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Iran Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Iran 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 326: Iran Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Iran Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Iran 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Iran 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 335: Israel Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Israel Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Israel 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 338: Israel Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Israel Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Israel 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Israel 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 347: Saudi Arabia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Saudi Arabia Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Saudi Arabia 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Saudi Arabia Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Saudi Arabia 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 359: UAE Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: UAE Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: UAE 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 362: UAE Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: UAE Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: UAE 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: UAE 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 371: Rest of Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Rest of Middle East Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: Rest of Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Middle East Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
  • AFRICA
    • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 383: Africa Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Africa Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: Africa 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
    • TABLE 386: Africa Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Africa Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: Africa 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: Africa 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제